Exenatide, the gliptins and detemir were all clinically effective. The long-acting insulin
analogues glargine and detemir appeared to have only slight clinical advantages over NPH …

Objective This study aimed to systematically review cost-effectiveness studies of newer
antidiabetic medications. Methods The PubMed/MEDLINE, EMBASE, CINAHL Plus …

BACKGROUND In recent years, meters for continuous monitoring of interstitial fluid glucose
have been introduced to help people with type 1 diabetes mellitus (T1DM) to achieve better …

Background: This analysis models the cost-effectiveness of real-time continuous glucose
monitoring (RT-CGM) using evidence from a randomized controlled trial (RCT) that …

BACKGROUND: In the past decade, many oncologic drugs have been approved that extend
life and/or improve patients' quality of life. However, new cancer drugs are often associated …

Objectives To conduct a systematic review and meta-analysis and to pool the incremental
net benefits (INBs) of glucagon-like peptide 1 (GLP1) compared with other therapies in type …

Abstract Aims/Introduction To investigate the direct medical costs for patients with type 2
diabetes in China and to examine the influencing factors. Materials and Methods In the …

Exenatide, administered subcutaneously twice daily (Byetta®), is a synthetic version of the
natural peptide exendin-4, which is a glucagon-like peptide-1 (GLP-1) receptor agonist …

Objective: Examine real-world effectiveness and hypoglycemia cost burden in patients with
type 2 diabetes newly initiated on exenatide or insulin glargine. Design and methods …

Objective: To identify and critically appraise cost-effectiveness models developed to
evaluate type 2 diabetes (T2D) treatments and to assess which types of treatment effects …